Core Viewpoint - The article highlights significant progress in the "2030 Pioneer Project" in Jiangxi Province, focusing on the biosynthesis and industrialization of functional nutritional products, including microbial proteins and vitamin B3 derivatives [1][3]. Group 1: Project Achievements - The project has developed efficient cell factories for microbial proteins, vitamin B3 derivatives, β-glucans, 2'-fucosyllactose, and L-valine, with some strains achieving internationally leading fermentation yields [3]. - The "Venetian Fusarium Protein" has been approved as a new food ingredient, marking China's first approval of filamentous fungal microbial protein, thus opening a new avenue for the microbial protein manufacturing industry [3]. - The pilot fermentation yield for vitamin B3 derivatives has reached over 40g/L, surpassing domestic and international reported levels, with a product purity of ≥99.5% [3]. Group 2: Industrialization and Economic Impact - The construction of production lines for tens of thousands of tons of microbial proteins and hundreds of tons of vitamin B3 derivatives is underway, expected to create a new food industry worth billions [3][4]. - The project aims to establish a high-level microbial protein manufacturing system to achieve large-scale, low-cost production, effectively replacing imported soybean protein [4]. Group 3: Collaborative Efforts - The project integrates efforts from enterprises, universities, and government, with Jiangxi Haiwen Biological Technology Co., Ltd. focusing on the entire vitamin B3 industry chain and addressing common industry challenges [5]. - The collaboration involves Jiangxi University and Jiangnan University leading the foundational technology development, while Haiwen Biological drives the industrialization of the technology [5].

Core Insights - The National Health Commission of China has approved "Venetian Sclerotium Protein" as a new food ingredient, marking it as the first filamentous fungus-derived microbial protein approved in the country [1] - This approval signifies Jiangxi Province's advancement in the forefront of microbial protein development and represents a milestone for the "2030 Pioneer Project" focused on high-quality microbial protein manufacturing [1][3] Industry Overview - Traditional protein sources heavily rely on livestock farming, which struggles to meet the increasing demand due to population growth and rising living standards, leading to environmental pollution and resource waste [3] - Filamentous fungus-derived microbial protein offers a sustainable alternative with high manufacturing efficiency and lower carbon emissions, contributing to national protein supply security and supporting carbon neutrality goals [3] Company Developments - Jiangxi Fuxiang Pharmaceutical Co., Ltd. has established a pilot production line for microbial protein with a capacity of thousands of tons, and is advancing the construction of a large-scale production line with an expected annual output of 20,000 tons [5] - The projected annual output value after full production is anticipated to exceed 2 billion yuan [5] - The company has completed regulatory submissions for its microbial protein in major international markets, including the US, Singapore, and Europe, establishing a development framework of "Jiangxi R&D, International Standards, Global Promotion" [5] Future Plans - Jiangxi Fuxiang Pharmaceutical aims to accelerate the transformation of its core brand "Weiran Protein" into downstream products such as plant-based meat and protein beverages, creating a complete industrial chain from technological innovation to consumer application [5] - The goal is to foster a biomanufacturing industry cluster worth 10 billion yuan [5]

Core Viewpoint - The announcement by the National Health Commission regarding the approval of new food materials, including the protein from the fungus Veneta, signifies a regulatory milestone for the company, allowing its subsidiary to produce and sell this new food ingredient domestically [1] Company Summary - Fujian Pharmaceutical (300497.SZ) announced that its subsidiary, Jiangxi Fujian Biotechnology Co., has successfully obtained administrative approval for the new food material application of Veneta fungus protein from the National Health Commission [1] - The approval indicates that the safety assessment materials submitted for Veneta fungus protein have been reviewed and passed by expert organizations [1] Industry Summary - The approval of Veneta fungus protein as a new food material aligns with the regulatory framework established by the Food Safety Law, highlighting the increasing acceptance of innovative food ingredients in the market [1] - This development may open new avenues for the production and commercialization of alternative protein sources within the food industry [1]

Core Viewpoint - The National Health Commission of China has approved the safety assessment of the new food ingredient, Venetian Sclerotium Protein, as part of its announcement regarding 14 new food items [1] Group 1 - The announcement is documented as No. 7 of 2025 by the National Health Commission [1] - The approval follows a review of safety assessment materials submitted for the new food ingredient [1] - The review was conducted by expert evaluators organized by the National Health Commission [1]